

**Table S1** The comparison between severe AKI and non-severe AKI

Variables	Non-severe AKI (n=121)	Severe AKI (n=13)	P value
Lymphocyte ( $\times 10^9/L$ )	1.8 $\pm$ 0.6	1.3 $\pm$ 0.7	<b>0.029</b>
Albumin (g/L)	40.8 $\pm$ 3.7	38.4 $\pm$ 3.0	<b>0.028</b>
Postoperative mPAP (mmHg)	22.1 $\pm$ 7.9	26.7 $\pm$ 6.8	<b>0.045</b>
Postoperative PVR (dyn·s·cm <sup>-5</sup> ·m <sup>2</sup> )	221.4 (144.7–349.2)	321.6 (225.6–492.4)	<b>0.033</b>
CPB time (h)	342.9 $\pm$ 59.7	379.3 $\pm$ 54.7	<b>0.037</b>
ACC time (h)	159.1 $\pm$ 40.9	184.9 $\pm$ 40.2	<b>0.032</b>
Mortality	5 (4.1)	3 (23.1)	<b>0.030</b>
MVT (h)	61.4 (39.3–91.0)	134.5 (45.0–328.8)	<b>0.007</b>
LOIS (d)	6.0 (3.0–8.5)	15.0 (5.0–36.5)	<b>0.025</b>

Bolded values represented P value <0.05. Continuous variables are presented as mean  $\pm$  standard deviation for normally distributed data or median (25<sup>th</sup>–75<sup>th</sup> percentile) for non-normally distributed data. Categorical variables are reported as frequencies (percentages). mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CPB, cardiopulmonary bypass; ACC, aortic cross-clamp; MVT, mechanical ventilation time; LOIS, length of intensive care unit stay.

**Table S2** Perioperative Quantitative Tendency of sCr and sMb

Variables	Full cohort (n=134)	Non-AKI (n=57)	AKI (n=77)	Severe AKI (n=13)	P value <sup>^</sup>	P value <sup>*</sup>
sCr ( $\mu$ mol/L)						
pre-sCr	74.7 (68.4–82.9)	72.1 (65.9–82.1)	77.1 (70.4–84.9)	78.7 (68.5–85.2)	0.068	0.747
POD0	78.0 (66.8–88.4)	71.8 (59.6–81.1)	85.4 (73.9–97.1)	86.8 (81.4–101.8)	<b>&lt;0.001</b>	<b>0.004</b>
POD1	100.5 (84.3–123.0)	84.3 (73.4–95.9)	117.6 (101.4–136.0)	126.3 (100.5–167.8)	<b>&lt;0.001</b>	<b>0.001</b>
POD2	86.4 (70.8–104.1)	72.8 (58.0–87.3)	96.1 (76.5–117.4)	136.3 (95.6–195.0)	<b>&lt;0.001</b>	<b>&lt;0.001</b>
POD3	74.4 (60.5–93.1)	64.1 (52.9–76.1)	85.2 (69.3–107.5)	132.1 (97.2–170.0)	<b>&lt;0.001</b>	<b>&lt;0.001</b>
POD4	68.8 (57.2–82.4)	65.3 (53.2–73.4)	71.5 (58.6–89.6)	117.9 (81.0–165.2)	<b>0.003</b>	<b>&lt;0.001</b>
POD5	67.0 (53.9–82.2)	60.5 (48.8–72.2)	74.2 (59.9–95.4)	121.7 (91.7–179.1)	<b>&lt;0.001</b>	<b>&lt;0.001</b>
POD6	63.7 (55.0–78.8)	59.5 (51.4–70.1)	70.1 (57.3–93.6)	113.7 (74.8–329.8)	<b>&lt;0.001</b>	<b>&lt;0.001</b>
POD7	67.7 (58.0–82.6)	61.4 (53.9–77.7)	70.5 (60.4–89.9)	89.3 (63.3–183.1)	<b>0.003</b>	<b>0.010</b>
sMb (ng/mL)						
pre-sMb	22.7 (14.7–28.2)	22.3 (14.9–27.5)	22.8 (14.2–29.7)	23.7 (17.1–30.8)	0.824	0.430
POD0	429.9 (303.7–714.6)	317.1 (235.4–415.3)	559.4 (415.5–844.0)	685.8 (482.9–959.5)	<b>&lt;0.001</b>	<b>0.005</b>
POD1	335.8 (229.8–527.5)	248.0 (169.2–355.7)	470.5 (293.1–624.3)	604.0 (336.0–885.5)	<b>&lt;0.001</b>	<b>0.002</b>
POD2	243.6 (158.8–429.4)	211.1 (134.2–300.4)	305.9 (204.0–471.4)	520.1 (235.5–700.5)	<b>0.001</b>	<b>0.003</b>
POD3	121.0 (72.2–242.7)	91.5 (55.1–142.1)	164.0 (90.1–287.1)	312.0 (136.6–595.9)	<b>&lt;0.001</b>	<b>0.002</b>

Bolded values represented P value <0.05. Median (25<sup>th</sup>–75<sup>th</sup> percentile) for non-normally distributed data. <sup>^</sup>, (AKI vs. non-AKI), patients with AKI (KDIGO stage 1 or higher) compared with patients without AKI. <sup>\*</sup>, (severe AKI vs. non-severe AKI), patients with severe AKI (KDIGO stage 2 and 3) compared with patients without AKI and patients with mild AKI (KDIGO stage 1). POD, postoperative day; sMb, serum myoglobin; sCr, serum creatinine.

**Table S3** The linear correlation between Ln(sCr) and Ln(sMb) in AKI

AKI	Ln(pre-sMb)	Ln(POD0-sMb)	Ln(POD1-sMb)	Ln(POD2-sMb)	Ln(POD3-sMb)
Ln(pre-sCr)	0.382**	0.17	0.133	0.170	0.094
Ln(POD0-sCr)	0.229*	0.484**	0.333**	0.235*	0.072
Ln(POD1-sCr)	0.244*	0.422**	0.504**	0.310**	0.123
Ln(POD2-sCr)	0.365**	0.223	0.336**	0.443**	0.506**
Ln(POD3-sCr)	0.308**	0.190	0.295**	0.364**	0.581**

\*\* , P<0.01; \* , P<0.05. POD, postoperative day; sMb, serum myoglobin; sCr, serum creatinine.

**Table S4** The linear correlation between Ln(sCr) and Ln(sMb) in severe AKI

Severe AKI	Ln(pre-sMb)	Ln(POD0-sMb)	Ln(POD1-sMb)	Ln(POD2-sMb)	Ln(POD3-sMb)
Ln(pre-sCr)	0.265	-0.04	-0.210	-0.397	-0.346
Ln(POD0-sCr)	0.439	0.224	-0.058	-0.193	-0.095
Ln(POD1-sCr)	0.114	0.597*	0.431	0.216	0.216
Ln(POD2-sCr)	0.220	0.609*	0.351	0.322	0.415
Ln(POD3-sCr)	0.390	0.526	0.397	0.380	0.529

\*\* , P<0.01; \* , P<0.05. POD, postoperative day; sMb, serum myoglobin; sCr, serum creatinine.

**Table S5** Univariate analysis of AKI

Variables	Univariate analysis		P value
	OR	95% CI	
<b>Demographic data</b>			
Age (years)	1.016	0.990–1.043	0.239
Male (%)	1.458	0.702–3.029	0.312
BMI (kg/m <sup>2</sup> )	1.073	0.965–1.192	0.194
<b>Blood type</b>			
A	1.000		0.264
AB	1.560	0.477–5.104	0.462
B	0.559	0.255–1.225	0.146
O	0.840	0.232–3.045	0.791
<b>Comorbidities (%)</b>			
Hypertension	1.894	0.838–4.281	0.125
Type 2 diabetes	0.422	0.096–1.842	0.251
Hyperlipidemia	1.080	0.524–2.225	0.835
CAD	3.188	0.651–15.627	0.153
COPD	1.185	0.506–2.772	0.696
<b>Laboratory tests</b>			
WBC (×10 <sup>9</sup> /L)	0.902	0.734–1.108	0.324
Neutrophil (×10 <sup>9</sup> /L)	0.897	0.696–1.154	0.397
Lymphocyte (×10 <sup>9</sup> /L)	0.825	0.484–1.406	0.479
Hemoglobin (×10 g/L)	0.937	0.788–1.114	0.460
Hematocrit (%)	0.982	0.921–1.048	0.582
Platelet count (×10 <sup>9</sup> /L)	0.999	0.994–1.005	0.834
Albumin (g/L)	1.054	0.960–1.158	0.269
D-dimer >0.5 (ng/mL)	1.542	0.762–3.120	0.229
Fibrinogen (g/L)	0.963	0.677–1.371	0.836
sCr (μmol/L)	1.023	0.996–1.049	0.092
eGFR (mL/min/1.73 m <sup>2</sup> )	0.989	0.968–1.010	0.286
Pre-sMb (ng/mL)	1.001	0.973–1.030	0.931
Ln(POD0-sMb)	6.785	3.101–14.725	<b>&lt;0.001</b>
<b>Nephrotoxic agents use (%)</b>			
ACEI/ARB	0.733	0.100–5.368	0.760
MRA	1.756	0.775–3.979	0.177
Diuretics	2.391	0.864–6.619	0.093
Antibiotics	0.850	0.270–2.681	0.782
Contrast media	1.536	0.439–5.375	0.502
<b>Preoperative TTE</b>			
RV basal diameter (mm)	1.022	0.982–1.064	0.288
mPA diameter (mm)	1.027	0.968–1.090	0.373
LVEF (%)	0.996	0.939–1.057	0.894
<b>Preoperative RHC</b>			
mPAP (mmHg)	1.055	1.021–1.090	<b>0.001</b>
PVR (dyn·s·cm <sup>-5</sup> ·m <sup>2</sup> )	1.001	1.000–1.001	0.118
CI (L/min)	0.969	0.666–1.410	0.871
<b>Postoperative RHC</b>			
mPAP (mmHg)	1.054	1.005–1.105	<b>0.031</b>
PVR (dyn·s·cm <sup>-5</sup> ·m <sup>2</sup> )	1.003	1.001–1.005	<b>0.007</b>
RPH (%)	1.600	0.755–3.389	0.220
<b>Intraoperative transfusion (%)</b>			
PRBCs	0.937	0.420–2.088	0.874
FFP	1.170	0.565–2.425	0.673
PLT	1.206	0.373–3.900	0.755
<b>Intraoperative details</b>			
Surgery time (min)	1.007	1.002–1.013	<b>0.004</b>
CPB time (min)	1.010	1.002–1.017	<b>0.008</b>
DHCA duration (min)	1.015	0.995–1.035	0.134
ACC time (min)	1.014	1.004–1.024	<b>0.005</b>
Concomitant surgery (%)	1.066	0.379–2.995	0.903
<b>UCSD classification</b>			
I	1.000		0.531
II	1.527	0.704–3.311	0.284
III	1.410	0.424–4.687	0.576

Bolded values represented P value <0.05. BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; POD, postoperative day; sMb, serum myoglobin; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; MRA, aldosterone receptor antagonist; TTE, echocardiography; RV, right ventricle; mPA, main pulmonary artery; LVEF, left ventricular ejection fraction; RHC, right heart catheterization; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CI, Cardiac output; RPH, residual pulmonary hypertension; PRBCs, packed red blood cells; FFP, fresh frozen plasma; PLT, platelet concentrates; CPB, cardiopulmonary bypass; DHCA, deep hypothermia circulatory arrest; ACC, aortic cross-clamp; UCSD, University of California at San Diego.

**Table S6** Univariate analysis of severe AKI

Variables	Univariate analysis		P value
	OR	95% CI	
<b>Demographic data</b>			
Age (years)	1.040	0.989–1.094	0.130
Male (%)	1.646	0.429–6.316	0.468
BMI (kg/m <sup>2</sup> )	1.027	0.866–1.219	0.758
<b>Blood type</b>			
A	1.000		0.714
AB	1.875	0.287–12.263	0.512
B	1.800	0.425–7.622	0.425
O	3.000	0.442–20.397	0.261
<b>Comorbidities (%)</b>			
Hypertension	1.290	0.371–4.488	0.689
Type 2 diabetes	1.357	0.154–11.983	0.783
Hyperlipidemia	0.836	0.243–2.877	0.776
CAD	2.568	0.484–13.623	0.268
COPD	1.796	0.510–6.331	0.362
<b>Laboratory tests</b>			
WBC (×10 <sup>9</sup> /L)	0.771	0.516–1.151	0.203
Neutrophil (×10 <sup>9</sup> /L)	0.887	0.568–1.385	0.597
Lymphocyte (×10 <sup>9</sup> /L)	0.327	0.117–0.912	<b>0.033</b>
Hemoglobin (×10 g/L)	0.846	0.643–1.112	0.230
Hematocrit (%)	0.965	0.867–1.075	0.519
Platelet count (×10 <sup>9</sup> /L)	0.999	0.991–1.008	0.881
Albumin (g/L)	0.854	0.739–0.988	0.033
D-dimer >0.5 (ng/mL)	2.519	0.777–8.163	0.123
Fibrinogen (g/L)	1.385	0.829–2.315	0.213
sCr (μmol/L)	1.006	0.966–1.049	0.758
eGFR (mL/min/1.73 m <sup>2</sup> )	0.989	0.955–1.025	0.549
Pre-sMb (ng/mL)	1.022	0.979–1.068	0.315
Ln(POD0-sMb)	4.045	1.446–11.321	<b>0.008</b>
<b>Nephrotoxic agents use (%)</b>			
ACEI/ARB	–	–	0.999
MRA	1.656	0.346–7.918	0.528
Diuretics	–	–	0.998
Antibiotics	1.818	0.357–9.272	0.472
Contrast media	2.018	0.392–10.401	0.401
<b>Preoperative TTE</b>			
RV basal diameter (mm)	1.054	0.983–1.130	0.140
mPA (mm)	1.084	0.998–1.178	0.056
LVEF (%)	0.940	0.856–1.032	0.191
<b>Preoperative RHC</b>			
mPAP (mmHg)	1.030	0.981–1.082	0.234
PVR (dyn·s·cm <sup>-5</sup> ·m <sup>2</sup> )	1.000	0.999–1.001	0.510
CI (L/min)	1.163	0.633–2.139	0.626
<b>Postoperative RHC</b>			
mPAP (mmHg)	1.069	1.000–1.143	0.051
PVR (dyn·s·cm <sup>-5</sup> ·m <sup>2</sup> )	1.002	1.000–1.005	0.104
RPH (%)	1.946	0.612–6.189	0.259
<b>Intraoperative transfusion (%)</b>			
PRBCs	2.176	0.658–7.199	0.203
FFP	1.266	0.389–4.118	0.696
PLT	3.330	0.786–14.103	0.102
<b>Intraoperative details</b>			
Surgery time (min)	1.004	0.997–1.011	0.226
CPB time (min)	1.008	1.000–1.016	0.055
DHCA duration (min)	1.009	0.980–1.038	0.558
ACC time (min)	1.014	1.001–1.027	<b>0.038</b>
Concomitant surgery (%)	2.293	0.562–9.348	0.247
<b>UCSD classification</b>			
I	1.000		0.467
II	0.455	0.092–2.250	0.334
III	1.614	0.302–8.611	0.575

Bolded values represented P value <0.05. BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; POD, postoperative day; sMb, serum myoglobin; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; TTE, echocardiography; RV, right ventricle; mPA, main pulmonary artery; LVEF, left ventricular ejection fraction; RHC, right heart catheterization; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CI, Cardiac output; RPH, residual pulmonary hypertension; PRBCs, packed red blood cells; FFP, fresh frozen plasma; PLT, platelet concentrates; CPB, cardiopulmonary bypass; DHCA, deep hypothermia circulatory arrest; ACC, aortic cross-clamp; UCSD, University of California at San Diego.

**Table S7** Collinearity statistics

Group	Collinearity, tolerance	Statistics, VIF
AKI		
Ln(POD0-sMb)	0.831	1.203
Postoperative PVR	0.883	1.133
Surgery time (min)	0.937	1.068
Severe AKI		
Albumin (g/L)	0.997	1.003
Ln(POD0-sMb)	0.997	1.003

AKI, acute kidney injury; POD0, postoperative day 0; PVR, pulmonary vascular resistance; VIF, variance inflation factor.